Search

Your search keyword '"Oers, M. H. J."' showing total 224 results
Start Over Author "Oers, M. H. J."
224 results on '"Oers, M. H. J."'

33. Profiling of volatile organic compounds produced by clinical Aspergillus isolates using gas chromatography-mass spectrometry

Author

Gerritsen, M G, Brinkman, P, Escobar Salazar, Natalia, Bos, L D, de Heer, K, Meijer, M, Janssen, H-G, de Cock, H, Wösten, H A B, Visser, C.E., van Oers, M H J, Sterk, P J, Gerritsen, M G, Brinkman, P, Escobar Salazar, Natalia, Bos, L D, de Heer, K, Meijer, M, Janssen, H-G, de Cock, H, Wösten, H A B, Visser, C.E., van Oers, M H J, and Sterk, P J

Abstract

Volatile organic compounds (VOCs) in exhaled breath may identify the presence of invasive pulmonary aspergillosis. We aimed to detect VOC profiles emitted by in vitro cultured, clinical Aspergillus isolates using gas chromatography-mass spectrometry (GC-MS). Three clinical Aspergillus isolates and a reference strain were cultured while conidiation was prevented. Headspace samples were analyzed using a standardized method. Breath samples of patients from which the cultures were obtained were checked for the presence of the VOCs found in vitro. Each Aspergillus isolate produced a distinct VOC profile. These profiles could not be confirmed in exhaled breath in vivo.

Published
2018

34. Profiling of volatile organic compounds produced by clinical Aspergillus isolates using gas chromatography-mass spectrometry

Author

Sub Molecular Microbiology, Molecular Microbiology, Gerritsen, M G, Brinkman, P, Escobar Salazar, Natalia, Bos, L D, de Heer, K, Meijer, M, Janssen, H-G, de Cock, H, Wösten, H A B, Visser, C.E., van Oers, M H J, Sterk, P J, Sub Molecular Microbiology, Molecular Microbiology, Gerritsen, M G, Brinkman, P, Escobar Salazar, Natalia, Bos, L D, de Heer, K, Meijer, M, Janssen, H-G, de Cock, H, Wösten, H A B, Visser, C.E., van Oers, M H J, and Sterk, P J

Published
2018

35. Treatment Of Gaucherʼs Disease

Author

Moscicki, Richard A., Taunton-Rigby, Alison, Barton, Norman W., Brady, Roscoe O., Dambrosia, James M., Grabowski, Gregory A., Hollak, Carla E.M., Aerts, J.M.F.G., van Oers, M. H. J., Sidransky, Ellen, Martin, Brian, Ginns, Edward I., Freiwald, David Ronald, Lexchin, Joel, Beutler, Ernest, Figueroa, Michael, Koziol, James, and Garber, Alan M.

Published
1993
Full Text
View/download PDF

36. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Author

Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P. -L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J., Seshan, V. E., Younes, A., Hilden, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., Seymour, J. F., Kelly, K., Gribben, J., Pfreunschuh, M., Morschhauser, F., Schoder, H., Zelenetz, A. D., Rademaker, J., Advani, R., Valente, N., Fortpied, C., Witzig, T. E., Sehn, L. H., Engert, A., Fisher, R. I., Zinzani, P. -L., Federico, M., Hutchings, M., Bollard, C., Trneny, M., Elsayed, Y. A., Tobinai, K., Abramson, J. S., Fowler, N., Goy, A., Smith, M., Ansell, S., Kuruvilla, J., Dreyling, M., Thieblemont, C., Little, R. F., Aurer, I., Van Oers, M. H. J., Takeshita, K., Gopal, A., Rule, S., de Vos, S., Kloos, I., Kaminski, M. S., Meignan, M., Schwartz, L. H., Leonard, J. P., Schuster, S. J., and Seshan, V. E.

Abstract

In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new basket clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [F-18]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

Published
2017

38. Profiling of volatile organic compounds produced by clinical Aspergillus isolates using gas chromatography-mass spectrometry

Author

Gerritsen, M G, Brinkman, P, Escobar Salazar, Natalia, Bos, L D, de Heer, K, Meijer, M, Janssen, H-G, de Cock, H, Wösten, H A B, Visser, C.E., van Oers, M H J, Sterk, P J, Sub Molecular Microbiology, Molecular Microbiology, Westerdijk Fungal Biodiversity Institute, Westerdijk Fungal Biodiversity Institute - Food and Indoor Mycology, Graduate School, Pulmonology, Other departments, Medical Microbiology and Infection Prevention, ARD - Amsterdam Reproduction and Development, ACS - Heart failure & arrhythmias, Supramolecular Separations (HIMS, FNWI), Sub Molecular Microbiology, and Molecular Microbiology

Subjects
0301 basic medicine, 030106 microbiology, Conidiation, Mass spectrometry, Aspergillosis, Gas Chromatography-Mass Spectrometry, 03 medical and health sciences, In vivo, Taverne, medicine, Humans, Invasive Pulmonary Aspergillosis, Aspergillus, Volatile Organic Compounds, Chromatography, biology, Chemistry, invasive pulmonary aspergillosis, exhaled breath analysis, General Medicine, Invasive pulmonary aspergillosis, biology.organism_classification, medicine.disease, gas chromatography-mass spectrometry, 030104 developmental biology, Infectious Diseases, Breath Tests, headspace analysis, Gas chromatography, Gas chromatography–mass spectrometry
Abstract

Volatile organic compounds (VOCs) in exhaled breath may identify the presence of invasive pulmonary aspergillosis. We aimed to detect VOC profiles emitted by in vitro cultured, clinical Aspergillus isolates using gas chromatography–mass spectrometry (GC-MS). Three clinical Aspergillus isolates and a reference strain were cultured while conidiation was prevented. Headspace samples were analyzed using a standardized method. Breath samples of patients from which the cultures were obtained were checked for the presence of the VOCs found in vitro. Each Aspergillus isolate produced a distinct VOC profile. These profiles could not be confirmed in exhaled breath in vivo.

Published
2016

39. Dutch guidelines for the diagnosis and treatment of chronic lymphocytic leukaemial

Author

Kersting, S., Levin, M-D., Chamuleau, M., Daenen, S. M. G. J., Dompeling, E. C., Doorduijn, J. K., van Gelder, M., Hoogendoorn, M., Kerst, J. M., Nijland, M., Nijziel, M. R., Posthuma, E. F. M., Raymakers, R. A. P., Schaafsma, M. R., Silbermann, M. H., van der Straaten, H. M., Veelken, J. H., Vos, J. M. I., Wittebol, S., van Oers, M. H. J., Kater, A. P., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Hematologie (9), Interne Geneeskunde, Hematology, CCA - Clinical Therapy Development, and Molecular cell biology and Immunology

Subjects
Chronic lymphocytic leukaemia, guidelines, HOVON, CLL
Abstract

In recent years, considerable progress has been made in the treatment of patients with chronic lymphocytic leukaemia (CLL). Therefore, the CLL working group of the Dutch/Belgium Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) framework revised the Dutch guidelines based on new studies and expert opinion of members of the working group.

Published
2016

43. Dutch guidelines for diagnosis and treatment of chronic lymphocytic leukaemia 2011

Author

Kater, A. P., Wittebol, S., Chamuleau, M. E. D., van Gelder, M., van Oers, M. H J, Interne Geneeskunde, and RS: GROW - School for Oncology and Reproduction

Subjects
Chronic lymphocytic leukaemia, guidelines, HOVON
Abstract

One of the principal responsibilities of the Chronic Lymphocytic Leukaemia (CLL) Working Party of the Dutch/Belgium Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) is to create up-to-date guidelines for CLL. In this article, the revised guidelines for diagnosis and treatment are summarised. Despite recent expansion in treatment options for patients with CLL, the disease remains incurable in most cases and the optimal treatment approach for several subgroups of patients is still unclear. Therefore, it remains highly important to treat patients within clinical studies as much as possible. In this article, the current studies initiated by the HOVON CLL working party are emphasised.

Published
2011

44. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells

Author

Thijssen, R, primary, ter Burg, J, additional, van Bochove, G G W, additional, de Rooij, M F M, additional, Kuil, A, additional, Jansen, M H, additional, Kuijpers, T W, additional, Baars, J W, additional, Virone-Oddos, A, additional, Spaargaren, M, additional, Egile, C, additional, van Oers, M H J, additional, Eldering, E, additional, Kersten, M J, additional, and Kater, A P, additional

Published
2015
Full Text
View/download PDF

49. Chronisch Lymfatische Leukemie (hoofdstuk 25)

Author

van Oers, M. H. J., Löwenberg, Bob, Ossenkoppele, Gert J., Amsterdam institute for Infection and Immunity, Cancer Center Amsterdam, and Clinical Haematology

Published
2008

50. Systematische diagnostiek van erytrocytose

Author

de Heer, K., Silbermann, M. H., Koene, H. R., Biemond, B. J., Muller, H. P., van Oers, M. H. J., Clinical Haematology, Amsterdam institute for Infection and Immunity, and Cancer Center Amsterdam

Abstract

Erythrocytosis is a phenomenon with life-threatening complications and a broad differential diagnosis. Erythrocytosis is usually secondary to a cardiopulmonary condition leading to a low arterial oxygen tension. A probable diagnosis can often be made on the basis of the history, physical examination, a measurement of the peripheral oxygen saturation, and simple laboratory tests. The differential diagnosis can be narrowed down by a determination of the erythropoietin concentration and the JAK2 mutation. If the erythrocytosis is found to be non-physiological, then reduction of the haematocrit via bloodletting and, depending on the diagnosis, treatment with acetylsalicylic acid are indicated

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results